Vertex Pharmaceuticals has won approval from the FDA for its non-opioid pain drug Journavx, which will treat moderate to severe acute pain after surgery or accidents. The twice-daily treatment was shown to be effective in late-stage trials, with patients experiencing less pain and fewer adverse events compared to a placebo. Priced at $31 per day, Journavx is forecasted to generate $1.5 billion in annual revenue by 2030, including potential sales for chronic pain.
Source: https://www.statnews.com/2025/01/30/vertex-pain-drug-journavx-wins-fda-approval-non-opioid